"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half ...

Shares of Moderna closed nearly 17% lower Monday. Other vaccine stocks also fell ... trial data Gilead says its twice-yearly shot cut HIV infections by 96% in trial The announcement comes as ...

Moderna's been anything but a high-flying growth stock in this investor's portfolio. So is it high time he gave up on this one? The post Moderna’s meant to be a red-hot growth stock. What on earth’s ...

Plus: A stomach flu vaccine, the health impacts of California’s wildfires, lots of nine-figure deals for healthcare startups ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally, posing a particularly significant threat to people with HIV ... to Moderna to develop mRNA vaccines against ...

Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of the virus is still being keenly felt.